

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions of claims in the application.

1.-2. (Cancelled)

3. (Currently Amended) An isolated polypeptide consisting of [[an]] the amino acid sequence from position 449 to position 687 in [[an]] the amino acid sequence shown in SEQ ID NO. 1.

4. (Cancelled)

5. (Withdrawn) An antibody capable of binding to a polypeptide or a peptide fragment derived from the polypeptide according to claim 3.

6. (Withdrawn) The antibody according to claim 5, which is present in blood of a patient positive for an anti-ADAMTS-13 antibody.

7. (Withdrawn) The antibody according to claim 5 or 6, which is present in blood of a patient with non-familial thrombocytopenic purpura (hereinafter, also referred to as TTP).

8. (Currently Amended) A reagent for antibody measurement comprising [[a]] the polypeptide of claim 3.

9. (Original) The reagent for antibody measurement according to claim 8, wherein an autoantibody in a TTP patient is an object to be detected.

10. (Currently Amended) A ~~pharmaceutical~~ composition ~~for treating a patient positive for an anti-ADAMTS-13 antibody~~ comprising, as an active ingredient, a polypeptide of claim 3.

11.-13. (Cancelled)

14. (Withdrawn) A method of producing blood or plasma free from an anti-ADAMTS 13 antibody by bringing a carrier bound with a polypeptide or a peptide fragment derived from the polypeptide according to claim 3 into contact with blood or plasma from a patient positive for an anti-ADAMTS-13 antibody and binding an anti-ADAMTS-13 antibody in the blood or the plasma to the ligand to remove the anti-ADAMTS-13 antibody from the blood or the plasma.